Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

43 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-13

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-tuberculous mycobacteria (NTM) are increasingly common and have a poor prognosis: 5-year mortality can reach 40 to 50%, depending on the type of mycobacteria and the immune system of the host involved. Cancer patients are at higher risk of infectious morbidity and mortality, which may be due to disease-related immune dysfunction, immunosuppressive effects of chemotherapy, or long-term placement of a vascular catheter. However, data on the treatment of NTM species that cause infections and the disease characteristics of these pathogens in cancer patients are limited despite the growing cancer population worldwide. Recently, M. avium infections have been described in patients suffering from cancers (hematological or not), in particular in patients receiving checkpoint inhibitors. Although the proportion of M. avium pneumonia in retrospective series is low (0.8-2%), it has been shown that this population is younger, suffers less from sub-pulmonary pathology. (indicating immunosuppression in these patients) but are therefore treated less than non-cancerous subjects.

This retrospective study in CHU Amiens is searching on the number of side effects of NTM treatment in two groups (cancerous and no cancerous) to assess the cause of the decrease of NTM treatment in cancerous patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections

NCT02355015

Mycobacterium Infections, Nontuberculous

UNKNOWN

State of Play of Non-tuberculous Mycobacteria in Alsace

NCT06185166

Non-Tuberculous Mycobacteria

RECRUITING

Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease

NCT01528930

Pulmonary Non-tuberculous Mycobacterial Lung Disease

WITHDRAWN PHASE2

A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy

NCT00002085

Mycobacterium Avium-Intracellulare Infection HIV Infections Tuberculosis, Mycobacterium Infection

COMPLETED NA

Liposomal Amikacin Inhalation in M.Abscessus Patients

NCT04163601

M.Abscessus Pulmonary Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mycobacterium Cancer Treatment Side Effects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cancerous patients

No interventions assigned to this group

non cancerous patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age equal or more than 18 years18
* Patients diagnosed by an infection with non-tuberculous mycobacteria according to ATS guidelines.
* Patients received the NTM treatment.

Exclusion Criteria

* age less than 18 years
* Patients diagnosed by NTM without treatment.
* Patients with a positive sample of NTM but without infection.
* Exclusion of other disorders such as tuberculous.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No